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Abstract
Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and
undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome
and facilitate discovery of phenotypic and prognostic biomarkers
Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every
6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS
National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional
samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months
Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time
from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease
activity, functional ability and health-related quality of life improved significantly between baseline and 24 months,
however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of
anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after
12 months. The SERA Biobank has accrued 60,612 samples
Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease
activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining
employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank
will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis
Background
Rheumatoid arthritis (RA) is the commonest auto-
immune inflammatory polyarthritis affecting approxi-
mately 0.8 % of the UK population [1, 2]. In the UK, an
estimated 12,000 new cases of RA are diagnosed each
year with an annual financial cost to the National Health
Service (NHS) approaching £4billion [3, 4]. The aetio-
pathogenesis of RA is complex, and incompletely under-
stood [5]. Genetic factors account for approximately
60 % of susceptibility to the disease [6], and many single
nucleotide polymorphisms and environmental factors
(e.g. cigarette smoking) have been associated with an
increased risk of developing RA [7, 8]. The prevailing
hypothesis is that when people with a genetic suscepti-
bility are exposed to an environmental trigger(s),
tolerance to certain self-antigens is lost (sometimes as
the result of citrullination of proteins) and an auto-
immune response that targets the synovium (amongst
other tissues) may develop [9].
In most patients, this process initially causes joint pain
and stiffness and may ultimately lead to irreversible joint
damage, disability and an impaired quality of life. In
addition, RA patients have an increased risk of co-
morbid conditions, including cardiovascular disease,
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infection and depression, and premature mortality [10–
13]. Despite these shared features, RA is a remarkably
heterogeneous disorder with a broad spectrum of disease
severity, phenotype and responsiveness to treatment
resulting in varying prognoses and outcomes. There is
increasing evidence of genetic and molecular heterogen-
eity of RA: for instance, anti-citrullinated protein anti-
body (ACPA) positive disease is associated with different
genetic (e.g. PTPN22) and environmental (e.g. smoking)
risk factors when compared to ACPA-negative disease
[14], and is associated with a higher rate of radiographic
progression [15].
Current guidelines emphasize the need for early inten-
sive treatment with disease modifying anti-rheumatic
drugs (DMARDs) to prevent or delay disease progres-
sion [3, 16]. However, there is striking heterogeneity of
treatment response and drug-related toxicity. Approxi-
mately 30 % of patients respond well to methotrexate
monotherapy [17, 18], whereas others are resistant to
multiple conventional and biologic DMARD therapies
given singly or in combination. However, most current
treatment strategies are empirical and it is not yet com-
mon practice to stratify treatment intensity based upon
an estimation of prognosis. The identification of bio-
markers that predict prognosis and drug responsiveness
might offer the potential to characterize disease hetero-
geneity further, and could potentially facilitate a strati-
fied treatment approach. Ultimately, the ability to treat
the right patient with the right drug at the right time,
could optimise response whilst minimizing toxicity. This
hope currently rests on the findings of high throughput
next generation sequencing techniques that can describe
patients’ molecular phenotype (genotype, transcriptome,
metabolome etc.) in unprecedented detail.
The long term course of RA appears to be changing,
which may be related to the revision of the classification
criteria, changing therapeutic paradigms, or alterations
in the disease itself. For instance, fewer patients require
major joint replacement surgery [19] and the incidence
of severe extra-articular manifestations is declining [20].
Data from historic RA cohorts may therefore no longer
be relevant to current RA patient populations. New, well
characterised cohorts, representative of current RA pa-
tients are required to help develop and implement
precision medicine as a useful clinical tool.
The Scottish Early Rheumatoid Arthritis (SERA) study
was designed to create a national inception cohort of
patients with newly diagnosed RA or undifferentiated
arthritis (UA), capturing longitudinal phenotypic and
outcome data, routine health service data, and an exten-
sive biobank of blood and urine samples. SERA aims to
provide:1. a detailed, contemporary description of the
phenotype, treatment and outcome of newly diagnosed
UA/RA patients in the 21st century, and 2. a resource
that facilitates translational and biomarker research
across multiple sequencing platforms. This report de-
scribes the study design, its Standard Operating Proce-
dures, the cohort’s baseline characteristics and short
term follow-up. It aims to raise awareness of the study’s
resources within the wider rheumatology and biomarker
research community in order to facilitate translational
research that contributes to the delivery of individualized
treatment for patients with RA.
Methods
Rheumatology units from across Scotland participate in
the SERA study. Patients with a new clinical diagnosis of
RA or UA, and who have at least one swollen joint, are
invited to participate. Patients are excluded if their joint
swelling can be explained by an alternative diagnosis
(e.g. psoriatic arthritis) or if they are carriers of blood
borne viruses. Duration of symptoms up until diagnosis
is not an exclusion criterion. Potential participants are
referred to local SERA research nurses for screening and
baseline assessments. Treatment decisions (including
initiation and escalation) and clinical follow-up remain
the responsibility of the local rheumatology department
who follow standard local practice. Patients are not ex-
cluded if treatment with steroids or DMARDs has
already started prior to recruitment (for example by the
General Practitioner) as long as the diagnosis of UA/RA
is new, and treatment has commenced within the last
6 months. Participants are asked to invite a first degree
relative, or friend of the same gender and similar age, to
participate in a cohort of healthy controls with a similar
genetic or demographic background. All participants
provide generic and enduring consent that allows: col-
lection of demographic and outcome data; retrieval and
linkage of routine health care data; and long term stor-
age of data and samples for future research projects.
Data collection
Research nurses assess participants every 6 months for
two years, and annually thereafter and are responsible
for assessment and collection of all of the outcome data.
Baseline and follow-up demographic and clinical out-
come data are collected in a standardized manner as de-
scribed in Additional file 1: Table S1. Laboratory values
for each visit are gathered from the hospital's laboratory
records. Study records are linked to the national data-
bases of the Information Services Division (ISD), NHS
National Services Scotland using each patient’s unique
Community Health Index (CHI) number. This allows
the acquisition of data relating to hospital admissions
(including diagnosis, operations, duration of stay), com-
munity prescription encashment, cancer diagnosis, ma-
ternal and fetal outcomes and death. Plain radiographs
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of both hands and both feet are collected at baseline and
after 12 months follow-up.
All clinical outcome data is captured within a be-
spoke, online electronic case report file (eCRF) that
is subject to a 6 month embargo to allow sufficient
time for data entry and resolution of data queries.
The presented results summarise all available data
relating to clinical and radiological outcomes at
baseline and over the first 24 months of follow-up in
the whole cohort.
Biological samples collection and storage
Additional blood and urine samples are collected at
baseline, 6 and 12 months from virtually all patients for
storage within the SERA Biobank. A detailed description
of the Standard Operating Procedures for sample acqui-
sition and storage is provided in Additional file 2. Briefly,
blood samples are either stored as whole blood (PAX-
gene RNA and EDTA), or as 500ul aliquots of serum
and plasma. If available, urine and surplus synovial fluid
is also retained within the biobank. All samples are ei-
ther stored locally in −80 °C freezers or are transferred
immediately to the central biobank, hosted by the NHS
Greater Glasgow & Clyde Bio-repository. The location
and quantity of all donated biological samples is tracked
using a bespoke Laboratory Information Management
System (LIMS) that links directly to each participant’s
electronic case report file (eCRF) and allows efficient
identification of samples relating to different phenotypic
subgroups
Governance
The SERA Study was initiated by the Scottish Collabora-
tive Arthritis Research (SCAR, www.scarnetwork.org)
network and represents a collaboration between the Uni-
versities of Aberdeen, Dundee, Edinburgh and Glasgow,
NHS Scotland, Healthcare Improvement Scotland, the
Chief Scientist’s Office Scotland and Pfizer Ltd. The
study’s protocol and procedures were reviewed and given
favourable opinion by the West of Scotland Research
Ethics Committee and all included patients provided
written, enduring consent to participate. The study is
managed by a scientific steering committee compris-
ing clinicians and academics, from each of the partici-
pating NHS Health Boards and Universities, and
(until April 2015) representatives of Pfizer Ltd. The
use of samples and data is governed by the SERA Ac-
cess Policy (Additional file 3) and any bona fide aca-
demic researcher may apply to use data and samples
subject to this policy. All applications are reviewed
and approved by the SERA Access Committee which
comprises the scientific steering committee and four
patient representatives.
Results
Recruitment commenced in September 2011. Patients
have been recruited from 16 rheumatology departments
from 10 Scottish NHS Health Boards. 1073 patients had
complete baseline data available in April 2015. Eighty-
nine healthy controls, comprising first degree relatives
or age and sex matched friends, have also been re-
cruited. 818 (76 %) of the patients fulfilled the 2010
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) Classification
Criteria for RA [21] at the baseline assessment, and 255
(24 %) patients were classified as UA. Nineteen (7 %) of
the UA patients were classified as RA during the first
2 years of follow-up. The baseline clinical and demo-
graphic features of the whole cohort are shown in
Table 1. Mean age at presentation was 58 years (SD ±
14), 698 patients (65 %) are female. 772 patients (72 %)
were positive for rheumatoid factor and 659 (61 %) were
positive for anti-CCP antibodies. The median time from
symptom onset to rheumatology referral was 115 (IQR
54–265) days and the median time from symptom onset
to first rheumatology clinic review was 163 (IQR 97–
323) days. Methotrexate was the first line DMARD in
810 (75 %) patients; of these 666 (82 %) received the first
prescription at or after, the baseline study assessment.
At the time of writing it was not possible to describe the
use of DMARD or biologic therapy during the follow-up
period. At the time of analysis, 830 patients had
attended for 6 months assessment, 670 had attended
for 12 months assessment, 378 had attended for
18 months assessment and 254 had attended for
24 months assessment.
Disease activity levels improved significantly between
baseline and month 24 follow-up (Fig. 1a). Mean DAS28
fell from 4.74 (SD ± 1.34) at baseline to 3.01 (SD ± 1.40)
after 24 months (p < 0.0001, paired t test). The greatest
rate of improvement in DAS28 occurred between base-
line and follow-up month 6. Mean change from baseline
of DAS28 was −1.55 (SD ± 1.67) after 6 months, −1.70
(SD ± 1.67) after 12 months and −1.73 (SD ± 1.80) after
24 months. The proportion of patients attaining DAS28
(<2.6) and Simplified Disease Activity Index (SDAI)
(<3.3) remission increased steadily over the follow-up
period (Fig. 1b) with rates of DAS28 remission being sig-
nificantly higher than SDAI remission at all time points.
All other ACR core set variables demonstrated signifi-
cant improvements from baseline during follow-up as-
sessments (data not shown).
There were significant improvements in functional
ability and health related quality of life during the
follow-up period (Figs. 2 and 3). The mean Health As-
sessment Questionnaire (HAQ) fell from 1.17 (SD ±
0.79) at baseline to 0.80 (SD ± 0.78) after 24 months (p <
0.0001, paired t test), whereas mean EuroQol 5D index
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increased from 0.51 (SD ± 0.32) to 0.66 (SD ± 0.30)
(p < 0.0001, paired t test)
At baseline, responses to the Hospital Anxiety and De-
pression Scale (HADS) questionnaire suggested that
23 % of patients reported symptoms of either anxiety
and/or depression. Based on the HADS questionnaire
responses, 11 % of patients were classified as probable
anxiety (anxiety scale ≥11), 4 % as probable depression
(depression scale ≥11) and 8 % with combined anxiety
and depression (both scales ≥11). Furthermore, the
Table 1 Baseline Clinical and Demographic Features
Whole Cohort
Number 1073
Females
N (%)
698 (65 %)
Age
Years
58 (±14)
BMI
BMI >30 N (%)
28 (±6.3)
358 (33 %)
Alcohol Excessa Males
N (%) Females
31 (8 %)
37 (5 %)
Current Smoker
N (%)
286 (27 %)
Rheumatoid Factor Positive
N (%)
772 (72 %)
Anti-CCP Antibody Positive
N (%)
659 (61 %)
Symptom duration until diagnosisb, days 163
(IQR 97–323)
DAS28 4.74 (±1.34)
28 Swollen Joint Count 7 (±6)
28 Tender Joint Count 8 (±7)
Patient Global 100mmVAS 52 (±28)
Physician Global 100 mm VAS 45 (±24)
Pain 100 mm VAS 52 (±28)
HAQ 1.17 (±0.8)
EQ5D Index 0.51 (±0.32)
HAD Anxiety Scale ≥11
N (%)
208 (19 %)
HAD Depression Scale ≥11
N (%)
138 (13 %)
ESRb 22 (IQR 12–41)
CRPb 12 (IQR 5–33)
Commenced Methotrexate
N (%)
810 (75 %)
Modified Sharp Score – Hands and Feet
Erosion scoreb
Joint space narrowing scoreb
Total Sharp Scoreb
0 (IQR 0–3.0)
0 (IQR 0–4.0)
2 (IQR 0–7.0)
Values are mean (SD) unless otherwise stated
aAlcohol excess – defined as greater than recommended weekly intake;
males >21units/week, females >14units/week
bMedian (IQR)
Fig. 1 Treatment response during first 24 months of follow-up. a.
mean DAS28, *p < 0.0001vs baseline. b percentage attainment of
DAS28ESR and SDAI remission, ♯p < 0.05 DAS28 vs SDAI
Fig. 2 Mean HAQ during first 24 months follow-up. *p < 0.0001
vs baseline
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proportion of patients reporting ongoing symptoms of
anxiety, depression and a combined anxiety-depression
disorder remained constant over the follow-up period
(Fig. 4). Despite this, the patients’ mean emotional dis-
tress scores (total HADS) fell significantly from 11.83
(SD ± 7.9) to 9.7 (SD ± 8.2) (p = 0.007, paired t test)
The crude proportion of patients in any employment
(full time, part time and self employed) fell significantly
from 51 % at baseline to 38 % after 24 months (p = 0.0005,
Chi square test) and was matched by a corresponding in-
crease in the proportion of patients classified as retired
(38 % at baseline, 49 % after 24 months, p = 0.002, CHI
square test) (Fig. 5). The proportion of patients classified
as unemployed remained static.
Three hundred and ninety one pairs of baseline x-rays
have been graded by a private company (Imaging
Rheumatology International) using the van der Heidje
modified Sharp Score [22]. On baseline images, 89
(23 %) of patients had erosions scores greater than zero
and 85 (22 %) had joint space narrowing scores greater
than zero. After 12 months follow-up, 35 (9 %) patients
demonstrated evidence of rapid radiographic progression
(increase in total modified-Sharp Score >5) [23]. The
median baseline values of the individual components of
the modified-Sharp Score are shown in table 2.
Additional resources
By April 2015, the SERA biobank had accrued 60,612
samples. Additional file 1: Table S2 describes the total
number of aliquots available of each sample type. Thir-
teen research applications to access SERA resource have
been approved (100 %), of which, 8 were for the use of
biobank samples. Approved biobank projects have in-
cluded, investigating the cohort’s DNA and RNA geno-
type, methotrexate pharmacogenetic profile, fine ACPA
epitope reactivity, urinary proteomic signatures [24] and
serum and urine metabolomics signatures.
Discussion
The SERA cohort provides a contemporary description
of the phenotype and outcome of RA/UA, as defined by
the 2010 ACR-EULAR Classification Criteria, in a rou-
tine secondary-care clinical environment. In this initial
description of the cohort, during the first 2 years of
treatment significant improvements in measures of
disease activity, functional ability and health related
quality of life were observed However, there were high
rates of ongoing psychiatric morbidity and a steady de-
cline in employment.
Recent international guidelines recommend a treat-to-
target approach that aims to achieve low disease activity
or remission in all patients [25, 26]. However, the SERA
study demonstrates that routine care of early RA in the
Fig. 3 Mean EuroQoL 5D Index during first 24 months of follow-up.*
p < 0.05 baseline vs 24 months
Fig. 4 Percentage of patients fulfilling Hospital Anxiety and
Depression Scale Criteria for probable anxiety (anxiety scale score
≥11), probable depression (depression scale score ≥11), probable
anxiety and depression (score ≥11 on anxiety and depression scales)
Fig. 5 Percentage patients classified as either in any employment,
unemployed or retired during first 24 months of follow-up.* p < 0.05,
baseline vs 24 months, any employment and retired
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NHS in Scotland only attains SDAI remission in a mi-
nority of cases (27 % after 12 months and 31 % after
24 months). DAS28 remission was achieved more fre-
quently (42 % after 12 months) and compared favorably
with the results from the UK-based Early RA Study
(DAS28 remission 21 % after 2 years) [27]. However,
DAS28 remission rates were lower than those observed in
the Dutch Rheumatoid Arthritis Monitoring (DREAM)
Remission Induction Cohort Study (DAS28 remission
58 % after 12 months), which used an aggressive step up
strategy with early biologic use [28], and the Tight Control
of RA (TICORA) study (DAS remission 62 % after
18 months) [29]. The lower remission rates observed in
SERA, when compared to DREAM and TICORA, could
reflect differences in the study populations, failure to
rigorously implement treat-to-target principles in routine
care, or potentially the more stringent eligibility criteria
for biologic therapy in the UK.
The time to initiation of DMARD is an important pre-
dictor of treatment response [30] and the results of the
SERA study demonstrate that Scottish rheumatologists
are seeing patients at an earlier stage in their disease
course than previously. In 2005–8, both phases of the
Clinical Audit of Care in Rheumatoid Arthritis (CARA)
in Scotland, demonstrated that the median time from
symptom onset to first rheumatology review was be-
tween 245 and 308 days [31] whereas in the SERA study
it was 163 days. Nonetheless, only 34 % of patients were
seen within 12 weeks of symptom onset, and a notable
minority of patients (23 %) already had radiographic
damage at their baseline assessment.
The SERA dataset also describes how other aspects
of patients’ lives may change following the diagnosis
of RA. The proportion of patients who remained in
any employment fell after diagnosis, even though
there were significant improvements in disease activ-
ity, functional ability and health related quality of life
observed over the same time period. The employment
rate changes observed in the SERA cohort are similar
to a recently published analysis of another UK-based
early RA cohort that demonstrated that the greatest
risk of work instability was within the first 2 years
after diagnosis [32]. Furthermore, the results demon-
strate that a significant proportion of patients (23 %
at baseline) report symptoms that are consistent with
anxiety and/or depression, which remained static dur-
ing follow-up. These findings are similar to previous
studies that used the HADS scale to describe the
prevalence of anxiety and/or depression in early and
established RA [33]. Taken together, these results em-
phasise that the diagnosis of RA can have a complex
impact on many different physical, psychological and
societal domains that may not be adequately ad-
dressed through solely pursuing DMARD-centric
treatment strategies that focus on the eradication of
inflammatory disease activity.
The size of the SERA study, the combination of
careful characterization of clinical phenotype, longi-
tudinal follow-up of outcomes and extensive biobank
are significant strengths and unique for an early RA
cohort. Furthermore, the ability to link to health ser-
vice utilization and prescription records has the po-
tential for the dataset to be used in a wide variety of
longitudinal epidemiology projects. The availability
of samples from healthy control patients is an im-
portant strength that will facilitate the identification
of disease related signatures; however, it is worth
highlighting the comparatively low number of
healthy controls compared to patients (89 vs 1073).
There is significant phenotypic overlap between RA
and UA, therefore we chose to initially analyse the
outcomes as a combined cohort, since in practice
many clinicians treat both conditions based upon the
same principles, though this may have skewed the
findings. A previous study suggests that the DAS28
may be a valid outcome measure in UA [34], but the
performance of the SDAI has not yet been validated.
The study also has other limitations: as a research
study, the patients that agree to participate may dif-
fer from those that decline; patients were recruited
soon after diagnosis but nonetheless baseline clinical
and laboratory findings may already have been al-
tered by prior treatment in primary care. Multiple
research nurses are employed throughout Scotland,
which may introduce variability in recording out-
come assessments (e.g. joint counts) and sample
transfer time to the biobank. Furthermore, storage of
biobank samples at −80 °C makes them unsuitable
for studies that require fresh blood.
Participants continue to be assessed by research
nurses, therefore the quantity of data available at each
assessment time point, and the duration of follow-up,
continues to increase. As the inception cohort and
biobank matures the developing datasets will provide
a very valuable tool for future clinical, epidemiological
and systems biology research. Each dataset is available
for analysis in isolation; however, it is hoped that the
availability of simultaneous clinical outcome data,
health records data and multiple sample types will en-
courage the conduct of an integrated, systems biology
analysis across multiple “omic platforms” that will in-
crease the likelihood of identifying clinically relevant
and reliable predictive signatures. All of the resources
described herein are available for use by bone fide re-
searchers to facilitate further RA research. Details on
the application procedure to access either clinical
data, and/or stored biobank samples, are available on
the SCAR website (www.scarnetwork.org).
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Additional file 1: Table S1. Baseline and Clinical Follow-up Data
Collection. Table S2. SERA Biobank. (DOC 49 kb)
Additional file 2: SERA Sample Handling SOP. (DOCX 100 kb)
Additional file 3: SERA Access Policy Holdings. (DOC 46 kb)
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